Zinc as supplements in treatment of schizophrenia
- Conditions
- Health Condition 1: F20- Schizophrenia
- Registration Number
- CTRI/2023/04/051490
- Lead Sponsor
- Central Institute of psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Male and female inpatients satisfying the ICD 10 - DCR [1993] criteria of Schizophrenia
2.Age group of 18-60 years.
3.Illness duration of minimum 2 years.
4.PANSS total score of minimum 80.
5.Those who give informed consent for participating in the study.
1.Any other major comorbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine.
2.Significant current/ past medical or neurological illness including severe hepatic disease and history of severe head injury.
3.Known hypersensitivity to Cap. Zinc Sulphate or any of its components.
4.Patients who had received ECT in the last 6 months.
5.Comorbid medical illness known to affect zinc levels including acute or chronic inflammatory
disorder and neurological disorder.
6.Patient on multivitamin supplementation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method